- Home
- GTX vs CELC Comparison
GTX vs CELC Comparison
Compare GTX & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GTX | CELC |
|---|---|---|
| Founded | 2018 | 2011 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 3.1B |
| IPO Year | 2021 | 2017 |
Fundamental Metrics
Financial Performance| Metric | GTX | CELC |
|---|---|---|
| Price | $18.00 | $107.46 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 8 |
| Target Price | $20.00 | ★ $106.63 |
| AVG Volume (30 Days) | ★ 1.8M | 549.5K |
| Earning Date | 04-30-2026 | 05-13-2026 |
| Dividend Yield | ★ 1.89% | N/A |
| EPS Growth | ★ 20.63 | N/A |
| EPS | ★ 1.52 | N/A |
| Revenue | ★ $3,584,000,000.00 | N/A |
| Revenue This Year | $4.80 | N/A |
| Revenue Next Year | $3.57 | N/A |
| P/E Ratio | $11.14 | ★ N/A |
| Revenue Growth | ★ 3.14 | N/A |
| 52 Week Low | $7.02 | $7.58 |
| 52 Week High | $21.42 | $120.32 |
Technical Indicators
Market Signals| Indicator | GTX | CELC |
|---|---|---|
| Relative Strength Index (RSI) | 46.37 | 44.74 |
| Support Level | $17.70 | $97.75 |
| Resistance Level | $19.28 | $117.27 |
| Average True Range (ATR) | 0.66 | 5.48 |
| MACD | -0.13 | -0.86 |
| Stochastic Oscillator | 43.82 | 24.09 |
Price Performance
Historical ComparisonAbout GTX Garrett Motion Inc.
Garrett Motion Inc designs, manufactures and sells engineered turbocharger and electric-boosting technologies for light and commercial vehicle original equipment manufacturers (OEMs). The company is a technology leader with expertise in delivering products across gasoline, diesel, natural gas and electrified powertrains. The company also sells its technologies in the aftermarket through its distribution network. The company derives maximum of its revenue from Gas and geographically from Europe.
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.